Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy. [electronic resource]
Producer: 20151120Description: 157-67 p. digitalISSN:- 1573-7217
- Adult
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers
- Breast Neoplasms -- drug therapy
- Disease Progression
- Female
- Humans
- Immunohistochemistry
- Leukocytes, Mononuclear -- metabolism
- Middle Aged
- Neoplasm Metastasis
- Neoplastic Cells, Circulating -- metabolism
- Receptor, ErbB-2 -- metabolism
- Retreatment
- Sirolimus -- administration & dosage
- TOR Serine-Threonine Kinases -- metabolism
- Trastuzumab -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.